Celcuity Inc. (CELC)
| Market Cap | 4.16B +78.0% |
| Revenue (ttm) | n/a |
| Net Income | -226.48M |
| EPS | -4.32 |
| Shares Out | 48.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 327,590 |
| Open | 85.22 |
| Previous Close | 82.58 |
| Day's Range | 84.76 - 87.50 |
| 52-Week Range | 44.42 - 151.02 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 161.09 (+89.52%) |
| Earnings Date | Aug 13, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $161.09, which is an increase of 89.52% from the latest price.
News
Celcuity initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Celcuity (CELC) with an Overweight rating and $157 price target The firm cites the long-term potential of Revtorpyk in breast cancer for the buy rating. The…
Celcuity Transcript: Citigroup’s Biopharma Back to School Summit 2026
REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and robust market access groundwork. Multiple phase III studies are ongoing in breast and prostate cancer, and expanded manufacturing is planned to support future growth.
Celcuity Transcript: Wells Fargo 21st Annual Healthcare Conference
REVTORPYK received approval for second-line metastatic breast cancer, with commercial launch planned this quarter and a supplemental NDA for PIK3CA mutant patients under review. Strong clinical data, flexible regimens, and a robust commercial strategy position the drug for significant market impact.
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid t...
Celcuity submits Revtorpyk sNDA to the FDA
Celcuity (CELC) announced the submission of its supplemental new drug application, or sNDA, to the FDA for Revtorpyk for the treatment of patients with hormone receptor positive, human epidermal growt...
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, ...
Celcuity price target raised to $175 from $165 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $175 from $165 and keeps a Buy rating on the shares. Celcuity remains well positioned ahead of…
Celcuity reports Q2 EPS ($1.07), consensus ($1.16)
“Celcuity (CELC) made monumental progress these past few months, achieving critical clinical and regulatory milestones related to gedatolisib. With the FDA approval of REVTORPYK, positive results from...
Celcuity price target lowered to $150 from $175 at Stifel
Stifel lowered the firm’s price target on Celcuity (CELC) to $150 from $175 and keeps a Buy rating on the shares. Management reiterated confidence in its ability to begin shipping…
Celcuity price target lowered to $140 from $157 at Needham
Needham lowered the firm’s price target on Celcuity (CELC) to $140 from $157 and keeps a Buy rating on the shares after its Q2 results and company’s updates following Revtorpyk’s…
Celcuity Earnings Call Transcript: Q2 2026
FDA approved REVTORPYK for HR-positive, HER2-negative advanced breast cancer, with commercial launch set for late Q3 2026 and a $6B+ U.S. market opportunity. Q2 net loss widened due to launch investments, but cash reserves are strong following a $575M convertible note.
Celcuity Earnings release: Q2 2026
Celcuity released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q2 2026
Celcuity has published its Q2 2026 quarterly earnings report on August 13, 2026.
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tu...
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of ...
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law.
Celcuity announces NCCN recommendation for Revtorpyk combination
Celcuity (CELC) announced that Revtorpyk in combination with fulvestrant, with or without palbociclib, is recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncol...
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutat...
Short Report: Bears book profits in Celcuity
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Celcuity price target raised to $178 from $171 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Celcuity (CELC) to $178 from $171 and keeps a Buy rating on the shares. Celcuity’s Revtorpyk approval came in as expected with a…
Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns overshadowed the com...
Celcuity price target raised to $155 from $145 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $155 from $145 and keeps a Buy rating on the shares following the FDA approval of Revtorpyk. Published first…
Celcuity price target raised to $177 from $160 at Citizens
Citizens raised the firm’s price target on Celcuity (CELC) to $177 from $160 and keeps an Outperform rating on the shares. Celcuity’s early FDA approval of Revtorpyk marks its transition…